SEARCH

SEARCH BY CITATION

References

  • 1
    Issacs A, Lindenmann J. Virus interference:I. The interferon. Proc R Soc [B] 1957; 147: 258267.
  • 2
    DeClerq E. Interferon inducers. Antibiot Chemother 1980; 27: 251287.
  • 3
    Stewart WEII. The Interferon System. New York: Springer-Verlag, 1981; 2757.
  • 4
    Goeddel DV, Leung DW, Dull TJ et al. The structure of eight distinct cloned human leukocyte interferon cDNAs. Nature 1981; 290; 2026.
  • 5
    Goeddel DV, Shepard HM, Yelverton E et al. Synthesis of human fibroblast interferon by E. coli. Nucleic Acids Res 1980; 8: 40574074.
  • 6
    Gray PW, Leung DW, Pennica D et al. Expression of human immune interferon cDNA in E. coli and monkey cells. Nature 1982; 295: 503508.
  • 7
    Clemens MJ, McNurlan MA. Regulation of cell proliferation and differentiation by interferons. Biochem J 1985; 226: 345360.
  • 8
    Borden EC. Progress toward therapeutic application of interferons, 1979–1983. Cancer 1984; 54: 27702776.
  • 9
    Strander H, Cantell K, Carlstrom G, Jakobsson PA. Clinical and laboratory investigations on man: Systemic administration of potent interferon to man. J Natl Cancer Inst 1973; 51: 733742.
  • 10
    Merigan TC, Sikora K, Breeden JH et al. Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. N Engl J Med 1978; 299: 14491453.
  • 11
    Gutterman JU, Blumenschein GR, Alexanian R et al. Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma and malignant lymphoma. Ann Intern Med 1980; 93: 399406.
  • 12
    Goeddel DV, Yelverton E, Ullrich A et al. Human leukocyte interferon produced by E. coli is biologically active. Nature 1980; 287: 411416.
  • 13
    Horning SJ, Levine JF, Miller RA et al. Clinical and immunologic effects of recombinant leukocyte A interferon in eight patients with advanced cancer. JAMA 1982; 247: 17181722.
  • 14
    Sherwin SA, Knost JA, Fein S et al. A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients. JAMA 1982; 248: 24612466.
  • 15
    Gutterman JU, Fine S, Quesada J et al. Recombinant leukocyte A interferon: Pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Intern Med 1982; 96: 549556.
  • 16
    Quesada JR, Gutterman JU. Clinical study of recombinant DNA-produced leukocyte interferon (clone A) in an intermittent schedule in cancer patients. J Natl Cancer Inst 1983; 70: 10411046.
  • 17
    Quesada JR, Hawkins M, Horning S et al. Collaborative phase I-II study of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma, and multiple myeloma. Am J Med 1984; 77: 427432.
  • 18
    Foon KA, Sherwin SA, Abrams PG et al. Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon. N Engl J Med 1984; 311: 11481152.
  • 19
    Schulof RS, Lloyd M, Stalling JJ et al. Recombinant leukocyte A interferon in B-cell chronic lymphocytic leukemia: In vivo effects on autologous antitumor immunity. J Biol Resp 1985; 4: 310323.
  • 20
    Foon KA, Bottino GC, Abrams PG et al. Phase II trial of recombinant leukocyte A interferon in patients with advanced chronic lymphocytic leukemia. Am J Med 1985; 78: 216220.
  • 21
    Bunn PA Jr, Foon KA, Ihde DC et al. Recombinant leukocyte A interferon: An active agent in advanced cutaneous T-cell lymphomas. Ann Intern Med 1984; 101: 484487.
  • 22
    Sherwin SA, Mayer D, Ochs JJ et al. Recombinant leukocyte A interferon in advanced breast cancer. Ann Intern Med 1983; 98: 598602.
  • 23
    Nethersell A, Smedley H, Katrak M, Wheeler T, Sikora K. Recombinant interferon in advanced breast cancer. Br J Cancer 1984; 49: 615620.
  • 24
    Neefe JR, Silgals R, Ayoob M, Schein PS. Minimal activity of recombinant clone A interferon in metastatic colon cancer. J Biol Resp 1984; 3: 366370.
  • 25
    Ernst P, Olesen BK, Nissen MH et al. In vivo effect of recombinant interferon (IFN) in patients with lung cancer. Proc Am Soc Clin Oncol 1984; 3: 66.
  • 26
    Grunberg SM, Kempf RA, Itri LM et al. Phase II study of recombinant alpha interferon in the treatment of advanced non-small cell lung carcinoma. Cancer Treat Rep 1985; 69: 10311032.
  • 27
    Niloff JM, Knapp RC, Jones GJ et al. Recombinant leukocyte alpha interferon in advanced ovarian carcinoma. Cancer Treat Rep 1985; 69: 895896.
  • 28
    Creagan ET, Ahmann DL, Green SJ et al. Phase II study of recombinant leukocyte A interferon (rIFN-αA) in disseminated malignant melanoma. Cancer 1984; 54: 28442849.
  • 29
    Creagan ET, Ahmann DL, Green SJ et al. Phase II study of low dose recombinant leukocyte A interferon in disseminated malignant melanoma. J Clin Oncol 1984; 2: 10021005.
  • 30
    Creagan ET, Ahmann DL, Green SJ et al. Phase II study of recombinant leukocyte A interferon (IFN-αA) plus cimetidine in disseminated malignant melanoma. J Clin Oncol 1985; 3: 977981.
  • 31
    Quesada JR, Rios A, Swanson D et al. Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol 1985; 3: 15221528.
  • 32
    Krown SE, Einzig AI, Abramson JD, Oettgen HF. Treatment of advanced renal cell cancer with recombinant leukocyte A interferon (rIFN-αA). Proc Am Soc Clin Oncol 1983; 2: 58.
  • 33
    Krown SE, Real FX, Krim M et al. Recombinant leukocyte A interferon in Kaposi's sarcoma. Ann NY Acad Sci 1984; 437: 431438.
  • 34
    Foon KA, Maluish AE, Abrams PG et al. A Phase II trial of recombinant leukocyte A interferon (rIFN-α A) for advanced hairy cell leukemia. Proc Am Soc Clin Oncol 1985; 4: 221.
  • 35
    Quesada JR, Hersh EM, Reuben J, Gutterman JU. Treatment of hairy cell leukemia (HCL) with recombinant-DNA derived interferon alpha (rIFN-α A). Proc Am Soc Clin Oncol 1985; 4: 222.
  • 36
    Trown PW, Dennin RA Jr, Kramer MJ et al. Antibodies to human leukocyte interferons in cancer patients. Lancet 1983; 1: 8184.
  • 37
    Foon KA, Dougher G. Increased growth of eyelashes in a patient given leukocyte A interferon. (Letter). N Engl J Med 1984; 311: 1259.
  • 38
    Averbuch SD, Austin HA III, Sherwin SA et al. Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte A interferon therapy for mycosis fungoides. N Engl J Med 1984; 310: 3235.
  • 39
    Stevenson HC, Ochs JJ, Halverson L et al. Recombinant alpha interferon in retreatment of two patients with pulmonary lymphoma. Am J Med 1984; 77: 355358.
  • 40
    Fer MF, Bottino GC, Sherwin SA et al. Atypical tumor lysis syndrome in a patient with T cell lymphoma treated with recombinant leukocyte interferon. Am J Med 1984; 77: 953956.
  • 41
    McLaughlin P, Talpaz M, Quesada JR. Immune thrombocytopenia following α-interferon therapy in patients with cancer. JAMA 1985; 254: 13531354.
  • 42
    Abrams PG, McClamrock E, Foon KA. Evening administration of alpha interferon. N Engl J Med 1985; 312: 443444.
  • 43
    Hawkins MJ, O'Connell MJ, Schiller JH et al. Phase I evaluation of recombinant A interferon alpha (rIFN-α A) in combination with COPA chemotherapy (I-COPA). Proc Am Soc Clin Oncol 1985; 4: 229.